Keywords: zymogenetics, 1st-qtr, loss, widens, seattle, usa-based, first-quarter
ZymoGenetics' 1st-qtr loss widens 22.8%
Article | 19 May 2008
Seattle, USA-based ZymoGenetics' first-quarter 2008 net loss totaled $70.9 million, or $0.60 per share, versus $33.0 million, or $0.49 per share, in the comparable period ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
